GeneralBody / AbdominalNeuro / Head & NeckNewsTrainee

FDA Clears Bayer's Low-Dose MRI Contrast Agent Ambelvist

Applied RadiologyJun 15

FDA approved Bayer's low-dose macrocyclic gadolinium-based contrast agent Ambelvist (gadopiclenol). Its high relaxivity permits a lower gadolinium dose for MRI, potentially reducing patient exposure.

  • Ambelvist (gadopiclenol) is a macrocyclic GBCA with high relaxivity, approved for use in adults and children.
  • The low-dose formulation may decrease cumulative gadolinium burden while maintaining diagnostic image quality.
  • This is a new agent in the U.S. market; clinical adoption and long-term safety data are pending.
Read the source

Also covered by

Automated summary

RadPigeon summaries are original and for information only. They are not clinical advice.